392 related articles for article (PubMed ID: 12408237)
1. Mechanistic approaches to Parkinson's disease pathogenesis.
Betarbet R; Sherer TB; Di Monte DA; Greenamyre JT
Brain Pathol; 2002 Oct; 12(4):499-510. PubMed ID: 12408237
[TBL] [Abstract][Full Text] [Related]
2. Ubiquitin-proteasome system and Parkinson's diseases.
Betarbet R; Sherer TB; Greenamyre JT
Exp Neurol; 2005 Feb; 191 Suppl 1():S17-27. PubMed ID: 15629758
[TBL] [Abstract][Full Text] [Related]
3. Pathogenesis of Parkinson's disease.
Sherer TB; Betarbet R; Greenamyre JT
Curr Opin Investig Drugs; 2001 May; 2(5):657-62. PubMed ID: 11569943
[TBL] [Abstract][Full Text] [Related]
4. Reprint of: revisiting oxidative stress and mitochondrial dysfunction in the pathogenesis of Parkinson disease-resemblance to the effect of amphetamine drugs of abuse.
Perfeito R; Cunha-Oliveira T; Rego AC
Free Radic Biol Med; 2013 Sep; 62():186-201. PubMed ID: 23743292
[TBL] [Abstract][Full Text] [Related]
5. Pathological proteins in Parkinson's disease: focus on the proteasome.
Snyder H; Wolozin B
J Mol Neurosci; 2004; 24(3):425-42. PubMed ID: 15655264
[TBL] [Abstract][Full Text] [Related]
6. Lentiviral vector delivery of parkin prevents dopaminergic degeneration in an alpha-synuclein rat model of Parkinson's disease.
Lo Bianco C; Schneider BL; Bauer M; Sajadi A; Brice A; Iwatsubo T; Aebischer P
Proc Natl Acad Sci U S A; 2004 Dec; 101(50):17510-5. PubMed ID: 15576511
[TBL] [Abstract][Full Text] [Related]
7. An in vitro model of Parkinson's disease: linking mitochondrial impairment to altered alpha-synuclein metabolism and oxidative damage.
Sherer TB; Betarbet R; Stout AK; Lund S; Baptista M; Panov AV; Cookson MR; Greenamyre JT
J Neurosci; 2002 Aug; 22(16):7006-15. PubMed ID: 12177198
[TBL] [Abstract][Full Text] [Related]
8. Molecular pathways of neurodegeneration in Parkinson's disease.
Dawson TM; Dawson VL
Science; 2003 Oct; 302(5646):819-22. PubMed ID: 14593166
[TBL] [Abstract][Full Text] [Related]
9. Alpha-synuclein and Parkinson's disease.
Golbe LI
Adv Neurol; 2003; 91():165-74. PubMed ID: 12442675
[No Abstract] [Full Text] [Related]
10. The A53T alpha-synuclein mutation increases iron-dependent aggregation and toxicity.
Ostrerova-Golts N; Petrucelli L; Hardy J; Lee JM; Farer M; Wolozin B
J Neurosci; 2000 Aug; 20(16):6048-54. PubMed ID: 10934254
[TBL] [Abstract][Full Text] [Related]
11. Impaired mitochondrial dynamics and function in the pathogenesis of Parkinson's disease.
Büeler H
Exp Neurol; 2009 Aug; 218(2):235-46. PubMed ID: 19303005
[TBL] [Abstract][Full Text] [Related]
12. Dopamine transporter-mediated cytotoxicity of 6-hydroxydopamine in vitro depends on expression of mutant alpha-synucleins related to Parkinson's disease.
Lehmensiek V; Tan EM; Liebau S; Lenk T; Zettlmeisl H; Schwarz J; Storch A
Neurochem Int; 2006 Apr; 48(5):329-40. PubMed ID: 16406146
[TBL] [Abstract][Full Text] [Related]
13. Role of protein aggregation in mitochondrial dysfunction and neurodegeneration in Alzheimer's and Parkinson's diseases.
Hashimoto M; Rockenstein E; Crews L; Masliah E
Neuromolecular Med; 2003; 4(1-2):21-36. PubMed ID: 14528050
[TBL] [Abstract][Full Text] [Related]
14. Interactions among alpha-synuclein, dopamine, and biomembranes: some clues for understanding neurodegeneration in Parkinson's disease.
Rochet JC; Outeiro TF; Conway KA; Ding TT; Volles MJ; Lashuel HA; Bieganski RM; Lindquist SL; Lansbury PT
J Mol Neurosci; 2004; 23(1-2):23-34. PubMed ID: 15126689
[TBL] [Abstract][Full Text] [Related]
15. Oxidative stress and genetics in the pathogenesis of Parkinson's disease.
Zhang Y; Dawson VL; Dawson TM
Neurobiol Dis; 2000 Aug; 7(4):240-50. PubMed ID: 10964596
[TBL] [Abstract][Full Text] [Related]
16. Co-association of parkin and alpha-synuclein.
Choi P; Golts N; Snyder H; Chong M; Petrucelli L; Hardy J; Sparkman D; Cochran E; Lee JM; Wolozin B
Neuroreport; 2001 Sep; 12(13):2839-43. PubMed ID: 11588587
[TBL] [Abstract][Full Text] [Related]
17. Mitochondrial dysfunction associated with increased oxidative stress and α-synuclein accumulation in PARK2 iPSC-derived neurons and postmortem brain tissue.
Imaizumi Y; Okada Y; Akamatsu W; Koike M; Kuzumaki N; Hayakawa H; Nihira T; Kobayashi T; Ohyama M; Sato S; Takanashi M; Funayama M; Hirayama A; Soga T; Hishiki T; Suematsu M; Yagi T; Ito D; Kosakai A; Hayashi K; Shouji M; Nakanishi A; Suzuki N; Mizuno Y; Mizushima N; Amagai M; Uchiyama Y; Mochizuki H; Hattori N; Okano H
Mol Brain; 2012 Oct; 5():35. PubMed ID: 23039195
[TBL] [Abstract][Full Text] [Related]
18. alpha-synuclein aggregation: a link between mitochondrial defects and Parkinson's disease?
Lee SJ
Antioxid Redox Signal; 2003 Jun; 5(3):337-48. PubMed ID: 12880487
[TBL] [Abstract][Full Text] [Related]
19. Parkinson's disease transgenic mitochondrial cybrids generate Lewy inclusion bodies.
Trimmer PA; Borland MK; Keeney PM; Bennett JP; Parker WD
J Neurochem; 2004 Feb; 88(4):800-12. PubMed ID: 14756800
[TBL] [Abstract][Full Text] [Related]
20. [Genetics and environmental factors of Parkinson disease].
Broussolle E; Thobois S
Rev Neurol (Paris); 2002 Dec; 158 Spec no 1():S11-23. PubMed ID: 12690660
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
